MAPP BIOPHARMACEUTICAL, INC.

Basic Information

6160 LUSK BLVD STE 105
SAN DIEGO, CA, 92121-2740

http://www.mappbio.com

Company Profile

n/a

Additional Details

Field Value
DUNS: 137551797
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: 24


  1. A human monoclonal for RSV prophylaxis

    Amount: $600,000.00

    DESCRIPTION (provided by applicant): Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract illness in infants and young children worldwide. In premature neonates, RSV infec ...

    SBIR Phase I 2014 Department of Health and Human Services
  2. Novel Immunotherapy for Brain Cancer

    Amount: $224,988.00

    DESCRIPTION (provided by applicant): Glioblastoma is the most common primary brain tumor in adults. While many patients achieve disease remission following treatment with surgical resection, radiatio ...

    SBIR Phase I 2014 Department of Health and Human Services
  3. An SEB Immunoprotectant

    Amount: $2,306,794.00

    DESCRIPTION (provided by applicant): Staphylococcal enterotoxin B (SEB; Category B agent), a toxin that commonly causes classic food poisoning and can cause a non-menstrual toxic shock syndrome (TSS) ...

    SBIR Phase II 2014 Department of Health and Human Services
  4. An Immunoprotectant for Marburg Virus

    Amount: $2,999,994.00

    DESCRIPTION (provided by applicant): Mortality rates associated with Marburg virus (MARV) outbreaks range from 20% to over 90%. MARV is included by the Centers for Disease Control and Prevention as am ...

    SBIR Phase II 2014 Department of Health and Human Services
  5. Ricin Toxin Protective Monoclonal Antibodies with Improved Serum Half-Life

    Amount: $99,949.00

    Ricin is a category B toxin due to its ease of acquisition, dissemination, and the high potential for morbidity and mortality after exposure. There are currently no methods of preventing or treating r ...

    SBIR Phase I 2014 ArmyDepartment of DefenseDepartment of Defense
  6. A Monoclonal Cocktail for CDI

    Amount: $299,986.00

    DESCRIPTION (provided by applicant): Clostridium difficile associated disease (CDI) is an important cause of morbidity in hospital and nursing home patients, and is being increasingly recognized as an ...

    SBIR Phase I 2012 Department of Health and Human Services
  7. A Monoclonal Antibody Immunoprotectant for Ebola Virus

    Amount: $3,000,000.00

    DESCRIPTION (provided by applicant): The National Institutes of Health considers the development of therapeutics against potential bioterrorism agents a national research priority. There is a particul ...

    SBIR Phase II 2011 Department of Health and Human Services
  8. Development of a monoclonal immunoprotectant for ricin

    Amount: $600,000.00

    DESCRIPTION (provided by applicant): The National Institutes of Health has deemed the development of therapeutics against potential bioterrorism agents as a national research priority. There is a part ...

    SBIR Phase I 2010 Department of Health and Human Services
  9. An Immunoprotectant for Marburg Virus

    Amount: $524,876.00

    DESCRIPTION (provided by applicant): Mortality rates associated with Marburg virus (MARV) outbreaks range from 23% to over 90%. MARV is included by the Centers for Disease Control and Prevention as am ...

    SBIR Phase I 2009 Department of Health and Human Services
  10. Monoclonal Antibody SEB Immunoprotectant

    Amount: $599,821.00

    DESCRIPTION (provided by applicant): Staphylococcal enterotoxin B (SEB; Category B agent), a toxin that commonly causes classic food poisoning and can cause a nonmenstrual toxic shock syndrome (TSS), ...

    SBIR Phase I 2008 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government